Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 25,165,859 shares, a drop of 5.3% from the December 14th total of 26,580,670 shares. Based on an average daily trading volume, of 1,514,190 shares, the short-interest ratio is presently 16.6 days. Currently, 27.7% of the shares of the stock are short sold.
Shares of SENS opened at $2.69 on Friday. Senseonics has a fifty-two week low of $2.26 and a fifty-two week high of $5.29.
Senseonics (NYSEAMERICAN:SENS) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $5.16 million during the quarter, compared to the consensus estimate of $5.16 million. During the same quarter in the prior year, the firm posted ($0.13) EPS. The company’s revenue for the quarter was up 145.7% on a year-over-year basis.
Separately, UBS Group initiated coverage on shares of Senseonics in a research report on Tuesday, November 27th. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Senseonics has an average rating of “Buy” and an average price target of $6.00.
TRADEMARK VIOLATION WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/4073357/short-interest-in-senseonics-holdings-inc-sens-declines-by-5-3.html.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
See Also: Back-End Load
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.